XML 104 R97.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 29, 2023
Dec. 14, 2023
Dec. 06, 2023
May 31, 2023
Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]                  
Common stock, shares issued 55,766,078 55,766,078 55,557,698            
Stock-based compensation   $ 25,575 $ 27,316 $ 27,500          
Aggregate intrinsic value of stock options exercised   $ 5,800 $ 14,100 $ 20,300          
Weighted average grant date fair value of share-based awards granted   $ 84.37 $ 87.40 $ 88.01          
Total fair value of stock options vested   $ 4,700 $ 3,100 $ 3,000          
Total unrecognized compensation cost $ 63,800 $ 63,800              
Unrecognized compensation cost, weighted average remaining requisite service period   2 years 10 months 2 days              
Number of unvested options and restricted stock units 2,185,873 2,185,873              
Avitide                  
Stockholders Equity Note Disclosure [Line Items]                  
Common stock, shares issued               42,621  
Earnout consideration earned               50.00%  
2018 Plan                  
Stockholders Equity Note Disclosure [Line Items]                  
Common stock shares reserved for Issuance                 2,778,000
Incentive options, vesting period 1,671,408 1,671,408              
Restricted Stock Units (RSUs)                  
Stockholders Equity Note Disclosure [Line Items]                  
Closing price of common stock         $ 179.80        
Unvested Options                  
Stockholders Equity Note Disclosure [Line Items]                  
Incentive options, vesting period   5 years              
Restricted Stock Units and Performance Stock Units                  
Stockholders Equity Note Disclosure [Line Items]                  
Aggregate intrinsic value of restricted stock units vested   $ 35,700 43,900 46,500          
Total grant date fair value of restricted stock units vested   $ 26,200 $ 22,700 $ 13,900          
1.00% Convertible Senior Notes due 2028                  
Stockholders Equity Note Disclosure [Line Items]                  
Net proceeds from public offering $ 14,400                
Repurchase of common stock (in shares) 92,090                
Closing price of common stock $ 156.22 $ 156.22         $ 156.2    
Share repurchase amount $ 25,000 $ 25,000              
Aggregate principal amount $ 600,000 $ 600,000       $ 290,100